Derechos | Equipo Nizkor
COVID booster recipients 20 times more protected against serious illness
A new study conducted in Israel shows that individuals given a third COVID-19 vaccine dose are nearly twenty times more protected against serious illness and more than ten times more protected against infection, compared with those who received their second dose at least five months previously.
The research, published on Wednesday by The New England Journal of Medicine, showed that 12 days after receiving a booster shot of a Pfizer-BioNTech COVID-19 vaccine, the chance of infection was 11.3 times less than among those eligible for a third shot but didn’t get one.
And the chance of suffering serious illness as a result of COVID-19 among those who had received a booster shot was 19.5 times less, the research said.
The study was conducted by researchers from the Weizmann Institute of Science, the Ministry of Health, the Technion, the Hebrew University, Sheba Medical Center, and the KI Institute.
Even with a more conservative analysis, which attempted to control possible behavioral differences between the two groups, the infection rate was at least 5 times lower in the group that had received the booster shot, the Health Ministry said in a statement.
The research includes data from more than 1 million Israelis. Among those who hadn’t received a booster shot despite being eligible, there were 4,439 confirmed infections, including 294 serious patients. Among those who received the booster at least 12 days previously, there were 934 infections including 29 serious cases.
The Israeli data could not say how long the boosted protection lasts.
But a separate study conducted at Sheba Medical Center in Ramat Gan, outside Tel Aviv, has stoked optimism as to the amount of time for which the booster shot retains its protection.
The study found that the antibody levels a week after the third COVID-19 vaccine dose was administered to its staff were ten times higher than their levels a week after the second dose was administered.
Israel — the first country to officially offer a third dose — began its COVID-19 booster campaign on August 1, initially rolling it out to those over the age of 60. It then gradually dropped the eligibility age, eventually expanding it to everyone aged 12 and up who received the second shot at least five months ago.
As of Thursday, nearly 3 million Israelis had received their third dose.
Meanwhile in the US, influential government advisers will debate Friday if there’s enough proof that a booster dose of Pfizer’s COVID-19 vaccine is safe and effective — the first step toward deciding which Americans need one and when.
The Food and Drug Administration on Wednesday posted much of the evidence its advisory panel will consider.
Pfizer’s argument is that while protection against severe disease is holding strong in the US, immunity against milder infection wanes somewhere around six to eight months after the second dose.
More important, Pfizer said, those antibodies appear strong enough to handle the extra-contagious Delta variant that is surging around the world.
To bolster its case, Pfizer pointed the FDA to the new data from Israel.
Pfizer said the data published on Thursday translates to “roughly 95% effectiveness” against Delta — comparable to the protection seen shortly after the vaccine’s rollout earlier in the year.
In Israel, the R-value — the reproduction rate of the virus measuring the average number of people each positive person infects — rose to 1.14 on Thursday, after it had hit a 4-month low of 0.81 just days earlier.
Any number over 1 indicates infections are rising, while a figure below that signals that an outbreak is abating.
There were 8,601 new COVID-19 cases diagnosed on Wednesday, according to the Health Ministry.
Of the 83,704 active cases, 654 are in serious condition. Since the start of the pandemic last year, 7,465 people have died of COVID-19 complications in Israel.
[Source: The Times of Israel, Agencies, Tel Aviv, 17Sep21]
|This document has been published on 20Sep21 by the Equipo Nizkor and Derechos Human Rights. In accordance with Title 17 U.S.C. Section 107, this material is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes.|